CleneCLNN
CLNN
About: Clene Inc is a clinical-stage pharmaceutical company pioneering the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. It is focused on the development of therapeutics for neurodegenerative diseases. It developed an electro-crystal-chemistry drug development platform that enables the production of concentrated, stable, clean-surfaced nanocrystal suspensions. It operates in one segment the development and commercialization of dietary supplements (Supplements). Products includes CNM-Au8, CNM-ZnA, CNM-AgZn17, rMetx, KHC46.
Employees: 76
0
Funds holding %
of 7,407 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
200% more first-time investments, than exits
New positions opened: 9 | Existing positions closed: 3
89% more call options, than puts
Call options by funds: $327K | Put options by funds: $173K
30% more funds holding
Funds holding: 20 [Q3] → 26 (+6) [Q4]
9.57% less ownership
Funds ownership: 15.69% [Q3] → 6.13% (-9.57%) [Q4]
33% less repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 6
44% less capital invested
Capital invested by funds: $4.66M [Q3] → $2.59M (-$2.07M) [Q4]
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$23
667%
upside
Avg. target
$27
800%
upside
High target
$31
933%
upside
2 analyst ratings
2 positive
100%
0 neutral
0%
0 negative
0%
D. Boral Capital Jason Kolbert 21% 1-year accuracy 74 / 353 met price target | 667%upside $23 | Buy Maintained | 8 Apr 2025 |
HC Wainwright & Co. Joseph Pantginis 15% 1-year accuracy 62 / 415 met price target | 933%upside $31 | Buy Reiterated | 8 Apr 2025 |
Financial journalist opinion
Based on 4 articles about CLNN published over the past 30 days
Neutral
GlobeNewsWire
5 days ago
Clene to Present at the Emerging Growth Conference
SALT LAKE CITY, April 14, 2025 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmaceutical company dedicated to advancing therapies for neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS), today announced that management will present at the Emerging Growth Conference.
Neutral
GlobeNewsWire
2 weeks ago
Clene to Present at the Jones Healthcare and Technology Innovation Conference
SALT LAKE CITY, April 01, 2025 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary, Clene Nanomedicine Inc., a late clinical-stage biopharmaceutical company focused on revolutionizing the treatment of neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS), today announced that management will present at the Jones Healthcare and Technology Innovation Conference and host 1x1 investor meetings.
Negative
Zacks Investment Research
3 weeks ago
Clene Inc. (CLNN) Reports Q4 Loss, Lags Revenue Estimates
Clene Inc. (CLNN) came out with a quarterly loss of $1.67 per share versus the Zacks Consensus Estimate of a loss of $1.21. This compares to loss of $1.20 per share a year ago.
Neutral
GlobeNewsWire
3 weeks ago
Clene Reports Full Year 2024 Financial Results and Recent Operating Highlights
SALT LAKE CITY, March 24, 2025 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a late clinical-stage biopharmaceutical company focused on revolutionizing the treatment of neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS), today announced its full year 2024 financial results and provided recent operating highlights for the clinical programs in ALS and MS.
Neutral
GlobeNewsWire
1 month ago
Clene Demonstrates Strengthened ALS Survival Benefit with CNM-Au8® Treatment
New Cross-Regimen Analysis of HEALEY ALS Platform Trial Shows Significant Survival Advantage New Cross-Regimen Analysis of HEALEY ALS Platform Trial Shows Significant Survival Advantage
Neutral
GlobeNewsWire
1 month ago
Clene to Present at the 37TH Annual Roth Conference
SALT LAKE CITY, March 06, 2025 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a late clinical-stage biopharmaceutical company focused on revolutionizing the treatment of neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS), today announced that management will participate in a fireside chat at the 37th Annual Roth Conference and host 1x1 investor meetings.
Neutral
Accesswire
1 month ago
Clene Inc. Rob Etherington, CEO, and Morgan Brown, CFO, to Present at the Investor Summit Virtual on March 11
NEW YORK, NY / ACCESS Newswire / February 27, 2025 / Rob Etherington, CEO, and Morgan Brown, CFO, of Clene Inc., will be presenting at this year's Investor Summit Virtual on March 11th. About Clene Inc. Clene Inc. is a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis, Parkinson's disease, and multiple sclerosis.
Neutral
GlobeNewsWire
1 month ago
Clene and APST Enter Into an Agreement to Support FDA's Recommendation for Long-Term NfL Biomarker Analyses of CNM-Au8®'s Impact on NfL Reduction
Longitudinal ALS patient data from APST Research will enable a more robust analysis of the effect of CNM-Au8 on NfL biomarkers APST Research data includes thousands of people living with ALS including clinical, survival, and longitudinal NfL data Clene plans to analyze the APST ALS NfL biomarker and clinical dataset to compare NfL change from its ongoing NIH-sponsored EAP to address the FDA's request for supportive evidence of CNM-Au8's effect on NfL reduction observed in the HEALEY ALS Platform Trial Clene plans to submit a New Drug Application (NDA) in second-half 2025 SALT LAKE CITY, Feb. 25, 2025 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a late clinical-stage biopharmaceutical company focused on revolutionizing the treatment of neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS), today announced that it has entered into an agreement with German-based APST Research GmbH (APST) to utilize its extensive NfL database to support the FDA-recommended analyses of CNM-Au8 ® 's effect on NfL decline in participants in ongoing Expanded Access Protocols (EAPs). APST maintains one of the largest comprehensive ALS repositories of people living with ALS, including demographic data, clinical data, ALS motor phenotypes and biomarker data, specifically, serum neurofilament light chain (sNfL).
Neutral
GlobeNewsWire
4 months ago
FDA Provides Roadmap for Accelerated Approval Pathway Through Submission of Additional CNM-Au8® Biomarker Data in ALS
SALT LAKE CITY, Dec. 10, 2024 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a late clinical-stage biopharmaceutical company focused on revolutionizing the treatment of neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS), today announced that it recently received written guidance from the Division of Neurology 1 (DN1), of the U.S. Food and Drug Administration (FDA) regarding a potential accelerated approval pathway for CNM-Au8 ® in ALS.
Negative
Zacks Investment Research
5 months ago
Clene Inc. (CLNN) Reports Q3 Loss, Misses Revenue Estimates
Clene Inc. (CLNN) came out with a quarterly loss of $1.22 per share versus the Zacks Consensus Estimate of a loss of $1.34. This compares to loss of $0.40 per share a year ago.
Charts implemented using Lightweight Charts™